| Literature DB >> 27815347 |
Helmut Fuchs1,2, Sibylle Sabrautzki1,3, Gerhard K H Przemeck1,2, Stefanie Leuchtenberger1, Bettina Lorenz-Depiereux4, Lore Becker1, Birgit Rathkolb1,2,5, Marion Horsch1, Lillian Garrett1,6, Manuela A Östereicher1, Wolfgang Hans1, Koichiro Abe7, Nobuho Sagawa7, Jan Rozman1,2, Ingrid L Vargas-Panesso1,8,9, Michael Sandholzer1, Thomas S Lisse1, Thure Adler1,10, Juan Antonio Aguilar-Pimentel1, Julia Calzada-Wack1,11, Nicole Ehrhard1,12, Ralf Elvert1, Christine Gau1, Sabine M Hölter1,6, Katja Micklich1,5, Kristin Moreth1, Cornelia Prehn1, Oliver Puk1,6, Ildiko Racz13, Claudia Stoeger1, Alexandra Vernaleken1,8,9, Dian Michel1, Susanne Diener4, Thomas Wieland4, Jerzy Adamski1,2, Raffi Bekeredjian14, Dirk H Busch15, John Favor4, Jochen Graw6, Martin Klingenspor16,17, Christoph Lengger1, Holger Maier1, Frauke Neff1,11, Markus Ollert18,19,20, Tobias Stoeger21, Ali Önder Yildirim21, Tim M Strom4, Andreas Zimmer13, Eckhard Wolf5, Wolfgang Wurst6,22,23,24, Thomas Klopstock8,9,22,24, Johannes Beckers1,2,25, Valerie Gailus-Durner1,2, Martin Hrabé de Angelis26,2,9,25.
Abstract
The vertebrate Scube (Signal peptide, CUB, and EGF-like domain-containing protein) family consists of three independent members, Scube1-3, which encode secreted cell surface-associated membrane glycoproteins. Limited information about the general function of this gene family is available, and their roles during adulthood. Here, we present the first Scube3 mutant mouse line (Scube3N294K/N294K), which clearly shows phenotypic alterations by carrying a missense mutation in exon 8, and thus contributes to our understanding of SCUBE3 functions. We performed a detailed phenotypic characterization in the German Mouse Clinic (GMC). Scube3N294K/N294K mutants showed morphological abnormalities of the skeleton, alterations of parameters relevant for bone metabolism, changes in renal function, and hearing impairments. These findings correlate with characteristics of the rare metabolic bone disorder Paget disease of bone (PDB), associated with the chromosomal region of human SCUBE3 In addition, alterations in energy metabolism, behavior, and neurological functions were detected in Scube3N294K/N294K mice. The Scube3N294K/N294K mutant mouse line may serve as a new model for further studying the effect of impaired SCUBE3 gene function.Entities:
Keywords: Paget disease of bone (PDB); SCUBE3; mouse model; pleitropy; systemic phenotype
Mesh:
Substances:
Year: 2016 PMID: 27815347 PMCID: PMC5144972 DOI: 10.1534/g3.116.033670
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Figure 1Skeletal abnormalities in Scube3 mice. (A) Femur length of female animals plotted by body length (red, Scube3 and blue, Scube3. (B) Bone mineral content plotted by body weight (green, Scube3 males; yellow, Scube3 females; blue, Scube3 males; and red, Scube3 females). (C) Bone mineral content plotted by body weight (green, Scube3 males; yellow, Scube3 females; blue, Scube3 males; red, Scube3 females).
Figure 2Statistically significantly changed clinical chemical and CTX-1 plasma values of aged groups of Scube3 mice measured at 12, 24, 36, and 52 wk of age. Red or blue filled arrows show significantly increased or decreased plasma values for female and male mice compared to Scube3WT mice (* P ≤ 0.05,** P = 0.01,*** P ≤ 0.001; nt = not tested). Unshaded but red or blue outlined arrows show a tendency to increased or decreased values not reaching statistically significance. Numbers of mice at 12 wk were female Scube3 mice n = 9, female Scube3 = 20, male Scube3 mice n = 21, and male Scube3 = 34; at 24 wk female Scube3 mice n = 10, female Scube3 = 21, male Scube3 mice n = 15, and male Scube3 = 29; at 36 wk female Scube3 mice n = 12, female Scube3 = 8, male Scube3 mice n = 25, and male Scube3 = 33; and at 52 wk: female Scube3 mice n = 12, female Scube3 = 8, male Scube3 mice n = 5, and male Scube3 = 11. For CTX-1 measurement at 52 wk, numbers were n = 10 mice for both female Scube3 mice and Scube3 mice, male Scube3 mice n = 9, and male Scube3 mice n = 10. ALB, albumin; ALP, total alkaline phosphatase; Ca, total inorganic calcium; CHO, cholesterol; CREA, creatinine; CTX-1, carboxy-terminal collagen crosslinks; GLUC, glucose; Pi, total inorganic phosphate; TG triglycerides; TP, total protein; UA, uric acid.
Figure 3Skeletal phenotypes of newborn Scube3 mice. Hyper-ossification of entire vertebrae in homozygous Scube3 mice (B and D) compared to wild-type mice (A and C). Asterisks in (B) indicate remarkable hyper-ossified vertebrae. Note that split ossification centers were detected in T10 and T11 (two asterisks in one vertebra). Sternebrae of Scube3 mice (D) were slightly thicker and longer than ones of wild-type mice (C). Asterisks in (D) indicate hyper-ossified sternebrae. Bones of upper and lower limbs in homozygous mutants (F and H) were also hyper-ossified compared to wild-type (E and G). Arrowhead indicate ossified coracoid process (E). Asterisks in (F) and (H) show representative hyper-ossified metacarpals, metatarsals, phalanx, and tarsals.
Renal function analysis
| Males | Females | 2-Way ANOVA ( | |||||
|---|---|---|---|---|---|---|---|
| Parameter | Genotype | Sex | Genotype × Sex | ||||
| Water uptake/25 g BW (g/24 hr) | 3.68 ± 0.81 | 6.01 ± 1.54 | 4.65 ± 1.88 | 6.88 ± 1.53 | < 0.001 | 0.039 | 0.910 |
| Urine excretion/25 g BW (g/24 hr) | 0.59 ± 0.31 | 1.1 ± 0.43 | 0.89 ± 0.57 | 1.20 ± 0.55 | 0.004 | 0.201 | 0.412 |
| Creatinine clearance/25g BW (µg/24 hr) | 583 ± 305 | 548 ± 265 | 812 ± 564 | 606 ± 191 | 0.246 | 0.168 | 0.409 |
| Na/25 g BW (µmol/24 hr) | 102 ± 50 | 208 ± 59 | 181 ± 105 | 205 ± 102 | < 0.001 | 0.004 | 0.803 |
| K/25 g BW (µmol/24 hr) | 228 ± 109 | 444 ± 131 | 392 ± 237 | 539 ± 192 | < 0.001 | 0.014 | 0.510 |
| Cl/25 g BW (µmol/24 hr) | 125 ± 62 | 262 ± 71 | 245 ± 154 | 364 ± 116 | < 0.001 | < 0.001 | 0.758 |
| Ca/25 g BW (µmol/24 hr) | 1.2 ± 0.6 | 2.3 ± 0.8 | 2.7 ± 1.5 | 4.1 ± 1.4 | < 0.001 | < 0.001 | 0.611 |
| Urea/25 g BW (mg/24 hr) | 60 ± 28.6 | 112 ± 31.9 | 111 ± 65.3 | 155 ± 44 | 0.099 | < 0.001 | 0.671 |
| Total protein/25 g BW (mg/24 hr) | 8.2 ± 3.5 | 11.8 ± 3.3 | 2.8 ± 1.9 | 3.7 ± 1.9 | 0.009 | < 0.001 | 0.107 |
| Albumin/25 g BW (µg/24 hr) | 98 ± 39 | 122 ± 31 | 108 ± 44 | 153 ± 50 | 0.008 | 0.109 | 0.411 |
| Glucose/25 g BW (µg/24 hr) | 210 ± 90 | 310 ± 94 | 427 ± 204 | 501 ± 121 | 0.030 | < 0.001 | 0.742 |
| FE Na (%) | 0.13 ± 0.05 | 0.30 ± 0.10 | 0.18 ± 0.05 | 0.33 ± 0.08 | < 0.001 | 0.149 | 0.656 |
| FE K (%) | 9.7 ± 3.1 | 20.4 ± 6.2 | 13.2 ± 3.3 | 21.7 ± 4.8 | < 0.001 | 0.082 | 0.422 |
| FE Cl (%) | 0.22 ± 0.08 | 0.52 ± 0.17 | 0.31 ± 0.08 | 0.57 ± 0.13 | < 0.001 | 0.061 | 0.672 |
| FE Ca (%) | 0.10 ± 0.03 | 0.20 ± 0.07 | 0.15 ± 0.02 | 0.28 ± 0.08 | < 0.001 | < 0.001 | 0.343 |
| FE urea (%) | 19 ± 4.9 | 34 ± 10.4 | 28 ± 6.6 | 41 ± 10.5 | < 0.001 | 0.002 | 0.708 |
| FE total protein (%) | 0.007 ± 0.003 | 0.012 ± 0.006 | 0.027 ± 0.009 | 0.045 ± 0.012 | < 0.001 | < 0.001 | 0.016 |
| FE albumin (%) | 0.00006 ± 0 | 0.00009 ± 0 | 0.00007 ± 0 | 0.00010 ± 0 | < 0.001 | 0.334 | 0.596 |
| FE glucose (%) | 0.029 ± 0.009 | 0.043 ± 0.010 | 0.019 ± 0.007 | 0.031 ± 0.010 | < 0.001 | < 0.001 | 0.720 |
ANOVA, analysis of variance; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; FE, calculated fractional excretion rate.
Functional classification of regulated genes in kidney
| Biological Functions and Disease | Genes | |
|---|---|---|
| Cellular development | 25 | |
| Cellular movement | 25 | |
| Cardiovascular system function | 24 | |
| Nervous system function | 20 | |
| Cell death and survival | 18 | |
| Neurological disease | 17 | |
| Cancer | 13 | |
| Cell cycle | 13 | |
| Cellular growth and proliferation | 12 | |
| Developmental disorder | 12 | |
| Renal and urological disease | 10 |
Shown are significantly (P < 0.05) enriched terms from the “biological functions and disease” analysis in Ingenuity Pathway Analysis.
Figure 4(A) Mild conductive hearing loss; asterisks mark genotype effect of both sexes together. * P < 0.05, ** P < 0.01, *** P < 0.001. (B) Abnormalities in inner ear development. Upper panel: depiction of smaller and malformed ossicles. The ambos (incus) has a different shape and the body of the hammer (malleus) is narrowed (arrow) and the head surface decreased. Lower panel: the whole inner and middle ear was reduced in size and, besides the alterations of the ossicles (arrow pointing toward the hammer, malleus), the auditory cavity (bulla) has an irregular shape (arrows). WT, wild-type.
Figure 5Analysis of Scube3 mice in the Open Field test and grip strength analysis. Data for distance traveled (A), number of rears (B), and percent time spent in center (C) are shown over the 20 min test interval. Grip strength (four paw measurement) is plotted vs. body weight (D) (green, Scube3 males; yellow, Scube3 females; blue, Scube3 males; and red, Scube3 females).
Figure 6(A) Fat mass plotted against body mass (green, Scube3 males; yellow, Scube3 females; blue, Scube3 males; and red, Scube3 females). (B) Lean mass plotted against body mass (green, Scube3 males; yellow, Scube3 females; blue, Scube3 males; and red, Scube3 females).
Figure 7Scube3 mice are homozygous for a (C) to (A) point mutation at nucleotide position 882 that leads to an asparagine to lysine exchange at protein position 294 (N294K) in exon 8 of Scube3 (A). The mutation affects the calcium-binding EGF-like domain VII (B), which might have effects on the capabilities to form homo- or heterodimers and block TGFβ/Hedgehog signaling (C), which causes phenotypic alterations in bone development and homeostasis, hearing ability, renal function, energy metabolism, neurological functions, and behavior. EGF, epidermal growth factor; TGFβ, transforming growth factor β.